肠道免疫因素在炎症性肠病中的研究进展及治疗策略

doi:10.3760/cma.j.issn.1007-1245.2024.04.011

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (4): 577-581.DOI: 10.3760/cma.j.issn.1007-1245.2024.04.011

肠道免疫因素在炎症性肠病中的研究进展及治疗策略

潘广涛¹ 陈爱莹²

¹盐城市中医院南京中医药大学附属盐城中医院，盐城　224000；²高邮市中医医院脾胃病科，高邮　225600

收稿日期:2023-07-26 出版日期:2024-02-01 发布日期:2024-03-07
通讯作者: 陈爱莹，Email：1549055667@qq.com
基金资助:
江苏省卫生健康委医学科研项目（Z2021068）；2021年盐城市医学科技发展计划重点项目（YK2021004）；2022年度江苏省科协青年科技人才托举工程（TJ-2022-097）

Research progress and treatment strategies of intestinal immune factors in inflammatory bowel disease

Pan Guangtao¹, Chen Aiying²

¹Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Yancheng 224000, China; ²Department of Spleen and Stomach Diseases, Gaoyou Hospital of Traditional Chinese Medicine, Gaoyou 225600, China

Received:2023-07-26 Online:2024-02-01 Published:2024-03-07
Contact: Chen Aiying, Email: 1549055667@qq.com
Supported by:
Fund of Jiangsu Provincial Health Commission (Z2021068); Yancheng Medical Science and Technology Development Plan Key Project in 2021 (YK2021004); Fund of Youth Science and Technology Talents Support Project of Jiangsu Association for Science and Technology in 2022 (TJ-2022-097)

摘要/Abstract

摘要：

炎症性肠病（inflammatory bowel disease，IBD）是由多种因素导致的肠道慢性炎症。近年来，随着研究的不断深入，肠道免疫因素逐渐受到临床及科研工作者的重视，为IBD的诊断和治疗提供了新兴研究方向。本文通过PubMed/Medline/Cochrane/SinoMed/知网/万方/维普等国内外医学数据库追溯了近20年的相关文献研究，对国内外文献中的肠道营养、肠道微环境、肠道氧供、肠道免疫因子以及昼夜节律等参与IBD发病的作用机制进行总结，旨在探索新的治疗靶点，为IBD的深入研究奠定基础。

关键词:

炎症性肠病, 免疫, 研究进展

Abstract:

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease caused by a variety of causes. In recent years, with the deepening of research, intestinal immune factors have gradually been paid attention to by clinical and researchers, providing an emerging research direction for IBD. We have traced related literature researches in the domestic and foreign medical databases such as PubMed/Medline/Cochrane/SinoMed/CNKI/Wanfang/CQVIP in the past 20 years, and summarize the mechanisms of intestinal nutrition, intestinal microenvironment, intestinal oxygen supply, intestinal immune factors, and circadian rhythm involved in the pathogenesis of IBD, in order to explore new therapeutic targets and lay a foundation for further study of IBD.

Key words:

Inflammatory bowel disease, Immunity, Research progress

潘广涛陈爱莹.

肠道免疫因素在炎症性肠病中的研究进展及治疗策略 [J]. 国际医药卫生导报, 2024, 30(4): 577-581.

Pan Guangtao, Chen Aiying.

Research progress and treatment strategies of intestinal immune factors in inflammatory bowel disease [J]. International Medicine and Health Guidance News, 2024, 30(4): 577-581.

参考文献

[1] Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology[J]. Lancet, 2007, 369(9573):1627-1640. DOI: 10.1016/S0140-6736(07)60750-8.
[2] Souza HN, Lora FL, Kulak CA, et al. Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density[J]. Arq Bras Endocrinol Metabol, 2008, 52(4):684-691. DOI: 10.1590/s0004-27302008000400015.
[3] Verway M, Behr MA, White JH. Vitamin D, NOD2, autophagy and Crohn's disease[J]. Expert Rev Clin Immunol, 2010, 6(4):505-508. DOI: 10.1586/eci.10.31.
[4] Polidoro L, Properzi G, Marampon F, et al. Vitamin D protects human endothelial cells from H₂O₂ oxidant injury through the Mek/Erk-Sirt1 axis activation[J]. J Cardiovasc Transl Res, 2013, 6(2):221-231. DOI: 10.1007/s12265-012-9436-x.
[5] Konijeti GG, Arora P, Boylan MR, et al. Vitamin D supplementation modulates T cell-mediated immunity in humans: results from a randomized control trial[J]. J Clin Endocrinol Metab, 2016, 101(2):533-538. DOI: 10.1210/jc.2015-3599.
[6] Kong J, Zhang Z, Musch MW, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier[J]. Am J Physiol Gastrointest Liver Physiol, 2008, 294(1):G208-G216. DOI: 10.1152/ajpgi.00398.2007.
[7] Mouli VP, Ananthakrishnan AN. Review article: vitamin D and inflammatory bowel diseases[J]. Aliment Pharmacol Ther, 2014, 39(2):125-136. DOI: 10.1111/apt.12553.
[8] Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity[J]. J Mol Med (Berl), 2010, 88(5):441-450. DOI: 10.1007/s00109-010-0590-9.
[9] Cantorna MT, Munsick C, Bemiss C, et al. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease[J]. J Nutr, 2000, 130(11):2648-2652. DOI: 10.1093/jn/130.11.2648.
[10] Jørgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study[J]. Aliment Pharmacol Ther, 2010, 32(3):377-383. DOI: 10.1111/j.1365-2036.2010.04355.x.
[11] Mathur J, Naing S, Mills P, et al. A randomized clinical trial of vitamin D3 (cholecalciferol) in ulcerative colitis patients with hypovitaminosis D3[J]. PeerJ, 2017, 5:e3654. DOI: 10.7717/peerj.3654.
[12] Siva S, Rubin DT, Gulotta G, et al. Zinc deficiency is associated with poor clinical outcomes in patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2017, 23(1):152-157. DOI: 10.1097/MIB.0000000000000989.
[13] Cleynen I, Vazeille E, Artieda M, et al. Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease[J]. Gut, 2014, 63(8):1265-1274. DOI: 10.1136/gutjnl-2012-303205.
[14] Singh S, Dulai PS, Zarrinpar A, et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(2):110-121. DOI: 10.1038/nrgastro.2016.181.
[15] McLaughlin SD, Walker AW, Churcher C, et al. The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing[J]. Ann Surg, 2010, 252(1):90-98. DOI: 10.1097/SLA.0b013e3181e3dc8b.
[16] Boirivant M, Cossu A. Inflammatory bowel disease[J]. Oral Dis, 2012, 18(1):1-15. DOI: 10.1111/j.1601-0825.2011. 01811.x.
[17] el-Omar E, Penman I, Cruikshank G, et al. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine[J]. Gut, 1994, 35(10):1385-1388. DOI: 10.1136/gut.35.10.1385.
[18] Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease[J]. J Crohns Colitis, 2014, 8(6):443-468. DOI: 10.1016/j.crohns.2013.12.013.
[19] 陈小丽,万珊珊,曹倩.炎症性肠病住院患者216例的难辨梭状芽孢杆菌感染危险因素和预后[J].中华消化杂志,2017,37(4):238-243. DOI:10.3760/cma.j.issn.0254-1432.2017. 04.004.
[20] 中华医学会消化病学分会炎症性肠病学组.炎症性肠病合并机会性感染专家共识意见[J].中华消化杂志,2017,37(4):217-226. DOI:10.3760/cma.j.issn.0254-1432.2017. 04.001.
[21] Hansen R, Russell RK, Reiff C, et al. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis[J]. Am J Gastroenterol, 2012, 107(12):1913-1922. DOI: 10.1038/ajg.2012.335.
[22] Schwiertz A, Jacobi M, Frick JS, et al. Microbiota in pediatric inflammatory bowel disease[J]. J Pediatr, 2010, 157(2):240-244.e1. DOI: 10.1016/j.jpeds.2010.02.046.
[23] Zhang SL, Wang SN, Miao CY. Influence of microbiota on intestinal immune system in ulcerative colitis and its intervention[J]. Front Immunol, 2017, 8:1674. DOI: 10.3389/fimmu.2017.01674.
[24] Tiratterra E, Franco P, Porru E, et al. Role of bile acids in inflammatory bowel disease[J]. Ann Gastroenterol, 2018, 31(3):266-272. DOI: 10.20524/aog.2018.0239.
[25] Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease[J]. Cell Host Microbe, 2014, 15(3):382-392. DOI: 10.1016/j.chom.2014.02.005.
[26] Willing B, Halfvarson J, Dicksved J, et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease[J]. Inflamm Bowel Dis, 2009, 15(5):653-660. DOI: 10.1002/ibd.20783.
[27] Ferreira-Halder CV, Faria AVS, Andrade SS. Action and function of Faecalibacterium prausnitzii in health and disease[J]. Best Pract Res Clin Gastroenterol, 2017, 31(6):643-648. DOI: 10.1016/j.bpg.2017.09.011.
[28] Del Chierico F, Abbatini F, Russo A, et al. Gut microbiota markers in obese adolescent and adult patients: age-dependent differential patterns[J]. Front Microbiol, 2018, 9:1210. DOI: 10.3389/fmicb.2018.01210.
[29] Degirolamo C, Rainaldi S, Bovenga F, et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice[J]. Cell Rep, 2014, 7(1):12-18. DOI: 10.1016/j.celrep.2014.02.032.
[30] Campbell EL, Bruyninckx WJ, Kelly CJ, et al. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation[J]. Immunity, 2014, 40(1):66-77. DOI: 10.1016/j.immuni.2013.11.020.
[31] Hatoum OA, Miura H, Binion DG. The vascular contribution in the pathogenesis of inflammatory bowel disease[J]. Am J Physiol Heart Circ Physiol, 2003, 285(5):H1791-H1796. DOI: 10.1152/ajpheart.00552.2003.
[32] Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension[J]. Proc Natl Acad Sci U S A, 1995, 92(12):5510-5514. DOI: 10.1073/pnas.92.12.5510.
[33] Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases[J]. Nat Rev Mol Cell Biol, 2004, 5(5):343-354. DOI: 10.1038/nrm1366.
[34] Chowdhury R, Hardy A, Schofield CJ. The human oxygen sensing machinery and its manipulation[J]. Chem Soc Rev, 2008, 37(7):1308-1319. DOI: 10.1039/b701676j.
[35] Ortiz-Barahona A, Villar D, Pescador N, et al. Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction[J]. Nucleic Acids Res, 2010, 38(7):2332-2345. DOI: 10.1093/nar/gkp1205.
[36] Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation[J]. J Clin Invest, 2022, 132(11):e159839. DOI: 10.1172/JCI159839.
[37] Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing[J]. Science, 2001, 292(5516):464-468. DOI: 10.1126/science.1059817.
[38] Van Welden S, Selfridge AC, Hindryckx P. Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(10):596-611. DOI: 10.1038/nrgastro.2017.101.
[39] 杨勇,张巍.炎症性肠病免疫发病机制的研究进展[J].中国实验诊断学,2012,16(1):181-183. DOI:10.3969/j.issn.1007-4287.2012.01.079.
[40] 张亚姝,成海燕(综述),邹颖(审校).Th9细胞及其与炎症性肠病关系的研究进展[J].医学研究生学报,2016,29(12):1334-1339. DOI:10.16571/j.cnki.1008-8199.2016.12.023.
[41] Chen Z, Yu K, Zhu F, et al. Over-expression of CD200 protects mice from dextran sodium sulfate induced colitis[J]. PLoS One, 2016, 11(2):e0146681. DOI: 10.1371/journal.pone.0146681.
[42] West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease[J]. Nat Med, 2017, 23(5):579-589. DOI: 10.1038/nm.4307.
[43] Swanson GR, Burgess HJ, Keshavarzian A. Sleep disturbances and inflammatory bowel disease: a potential trigger for disease flare?[J]. Expert Rev Clin Immunol, 2011, 7(1):29-36. DOI: 10.1586/eci.10.83.
[44] Liang X, Bushman FD, FitzGerald GA. Rhythmicity of the intestinal microbiota is regulated by gender and the host circadian clock[J]. Proc Natl Acad Sci U S A, 2015, 112(33):10479-10484. DOI: 10.1073/pnas.1501305112.
[45] Tang X, Guo D, Lin C, et al. hCLOCK causes rho-kinase-mediated endothelial dysfunction and NF-κB-mediated inflammatory responses[J]. Oxid Med Cell Longev, 2015, 2015:671839. DOI: 10.1155/2015/671839.
[46] Yu X, Rollins D, Ruhn KA, et al. TH17 cell differentiation is regulated by the circadian clock[J]. Science, 2013, 342(6159):727-730. DOI: 10.1126/science.1243884.
[47] Arjona A, Sarkar DK. The circadian gene mPer2 regulates the daily rhythm of IFN-gamma[J]. J Interferon Cytokine Res, 2006, 26(9):645-649. DOI: 10.1089/jir.2006.26.645.
[48] 谢成,晏维,付妤.生物钟与炎症性肠病[J].临床消化病杂志,2016,28(6):390-393. DOI:10.3870/lcxh.j.issn.1005- 541X.2016.06.19.

肠道免疫因素在炎症性肠病中的研究进展及治疗策略

Research progress and treatment strategies of intestinal immune factors in inflammatory bowel disease

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	陈妙玲韩玉贞. PD-L1与肿瘤相关巨噬细胞在乳腺癌中的研究进展 [J]. 国际医药卫生导报, 2024, 30(5): 732-735.
[2]	刘红杰李星程晓. 细菌溶解产物联合甲强龙对支气管肺炎患儿的疗效 [J]. 国际医药卫生导报, 2024, 30(4): 540-544.
[3]	胡少博张娜莉程静梅. 血清KL-6水平与NSCLC患者PD-1相关免疫性肺炎的关联性 [J]. 国际医药卫生导报, 2024, 30(4): 602-605.
[4]	姜军选方圆. 补中益气汤在驱动基因阴性NSCLC免疫治疗中的应用价值 [J]. 国际医药卫生导报, 2024, 30(2): 305-309.
[5]	袁燕平张卢舜. Wnt蛋白在皮肤鳞状细胞癌与基底细胞癌中的表达情况研究 [J]. 国际医药卫生导报, 2024, 30(1): 33-37.
[6]	李逸群易丽君陈庆勇李云荣李红安姝憬. 喉鳞状细胞癌中HPV与TAP、CD8、HLA表达的相关性及临床意义 [J]. 国际医药卫生导报, 2024, 30(1): 112-119.
[7]	刘玉姣王超刘菲. 中西医结合治疗产后盆底肌筋膜疼痛的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1204-1207.
[8]	柯金王恒石张善兰. 卡瑞利珠单抗免疫相关不良反应临床分析 [J]. 国际医药卫生导报, 2023, 29(9): 1258-1262.
[9]	黄育涛王鸿武. 儿童原发性免疫性血小板减少症预后因素的研究 [J]. 国际医药卫生导报, 2023, 29(8): 1117-1121.
[10]	张衡潘广涛殷鸣张平尹霞. 自体脂肪移植在整形外科中的研究进展 [J]. 国际医药卫生导报, 2023, 29(7): 889-892.
[11]	姚文杰宋凯雨姜冠桐陈茜周瑾. 桥本甲状腺炎的研究进展 [J]. 国际医药卫生导报, 2023, 29(6): 741-744.
[12]	吴雪梅张玉杰解胜华. 银屑病与心血管共病关系的研究进展 [J]. 国际医药卫生导报, 2023, 29(4): 453-456.
[13]	袁晓莉王振波. 食管鳞癌的肿瘤免疫微环境和免疫检查点抑制剂研究进展 [J]. 国际医药卫生导报, 2023, 29(3): 310-314.
[14]	凌娟曾慧兰. 双特异性抗体在复发难治多发性骨髓瘤中的治疗进展 [J]. 国际医药卫生导报, 2023, 29(3): 319-323.
[15]	詹霞李志霞. 特发性肥厚性硬脑脊膜炎1例 [J]. 国际医药卫生导报, 2023, 29(3): 430-433.